Aikido Pharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $19.53 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aikido Pharma Inc had its IPO on 1984-09-07 under the ticker symbol AIKI.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Aikido Pharma Inc has a staff strength of 4 employees.
Shares of Aikido Pharma Inc opened at $3.85 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $3.8 - $3.88, and closed at $3.8.
This is a -2.81% slip from the previous day's closing price.
A total volume of 10,734 shares were traded at the close of the day’s session.
In the last one week, shares of Aikido Pharma Inc have slipped by -5.94%.
Aikido Pharma Inc's Key Ratios
Aikido Pharma Inc has a market cap of $19.53 million, indicating a price to book ratio of 0.2466 and a price to sales ratio of 2601.0981.
In the last 12-months Aikido Pharma Inc’s revenue was $9000 with a gross profit of $9000 and an EBITDA of $-1774750. The EBITDA ratio measures Aikido Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aikido Pharma Inc’s operating margin was 0% while its return on assets stood at -9.1% with a return of equity of -18.01%.
In Q3, Aikido Pharma Inc’s quarterly earnings growth was a negative -96.7% while revenue growth was a negative 67.9%.
Aikido Pharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.849 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aikido Pharma Inc’s profitability.
Aikido Pharma Inc stock is trading at a EV to sales ratio of 9706.6226 and a EV to EBITDA ratio of 1.5691. Its price to sales ratio in the trailing 12-months stood at 2601.0981.
Aikido Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $84.45 million
- Total Liabilities
- $1.90 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aikido Pharma Inc ended 2023 with $84.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $84.45 million while shareholder equity stood at $81.85 million.
Aikido Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $1.90 million in other current liabilities, in common stock, $-178625000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.50 million and cash and short-term investments were $42.56 million. The company’s total short-term debt was $42,000 while long-term debt stood at $0.
Aikido Pharma Inc’s total current assets stands at $56.09 million while long-term investments were $26.09 million and short-term investments were $8.07 million. Its net receivables were $8.65 million compared to accounts payable of $518000.00 and inventory worth $0.
In 2023, Aikido Pharma Inc's operating cash flow was $-681000.00 while its capital expenditure stood at $0.
Comparatively, Aikido Pharma Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aikido Pharma Inc stock is currently trading at $3.8 per share. It touched a 52-week high of $10.2 and a 52-week low of $10.2. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $3.7 and 200-day moving average was $5.2 The short ratio stood at 2.31 indicating a short percent outstanding of 0%.
Around 1322.7% of the company’s stock are held by insiders while 1086.9% are held by institutions.
Frequently Asked Questions About Aikido Pharma Inc
Similar Industry Stocks (Biotechnology & Medical Research)
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.